P804 Prevalence of fybromialgia in IBD patients: a single-centre observational prospective study

Abstract

Background: Joint pain is frequently reported by IBD patients and can be associated to extraintestinal manifestations of diseases, comorbidity or adverse events associated to anti-TNF or vedolizumab therapy. An appropriate rheumatological referral is crucial to drive an appropriate therapeutic strategy in case of concomitant spondyloarthritis. Fybromyalgia (FM) is a frequent cause of chronic pain that need to be identify in order to not overestimate the prevalence of SpA in IBD patients. Aim of the study was to assess the prevalence of FM in a cohort of IBD outpatients. Methods: Consecutive patients of the IBD Unit coming for a routine visit were screened by a rheumatologist in order to identify cases presenting the 2010 ACR criteria for FM or ASAS criteria for SpA. Patients affected by other rheumatic conditions such as rheumatoid arthritis and microcrystalline arthritis were excluded from the study. The rheumatological assessment included a joint cunt of 66 SJ and 68 TJ, MASEI, LEI and the fibromyalgia tender points examination. The patient completed BASDAI and BANSFI in the day of clinical evaluation. Imaging exams (MSK ultrasound, MRI) and HLAB27 determination were requested if needed for diagnostic purpose. Results: Between January to May 2018 210 patients were enrolled in the study and 181 complete the clinical-imaging examination. . Thirty-four patients (18.8%) presented the criteria for primary FM, 58 patients presented ASAS criteria for SpA (32%).In the group of SpA patients 10 patients presented a concomitant FM. A total of 44 patients (24.3%) in our IBD cohort presented the ACR 2010 criteria for FM. Of note FM patients presented LEI; BASDAI and BANSFI scores higher than SpA patients. Conclusions: FM is a common comorbidity in IBD patients and can be associated to SpA. An appropriate rheumatological referral is crucial to exclude a concomitant SpA and to manage FM.